Lab's Journal CLub - 14th of September 2020

Don't miss the journal club of Monday, 14th of September 2020.

Benjamin CAULIER, Postdoc, will present an article published in Immunity that deals with sustainability of CAR expression and response persistence using Ubiquitination modifications.


Credits: From Wentao Li et al:, Article in Immunity Volume 53, ISSUE 2, P456-470.e6, August 18, 2020

The journal club will take place in the usual 5th floor meeting room after the lab meeting (around 12h). See you there !

The Translational Research Unit will present some papers at the Immunology Journal Club on Friday 4th of September 2020 !

Hakan Köksal will present: Designed protein logic to target cells with precise combinations of surface antigens (Marc J. Lajoie et al., 2020) (

Nadia Mensali will present: An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma ( Ugur Sahin et al., 2020) (

The Zoom link will be uptaded soon, make sure to schedule this event in your agenda !

The Translational Research Unit has licensed NK-TCR to Zelluna Immunotherapy

The Norwegian biotech Zelluna Immunotherapy, based on a licence from our Translational Research Unit (Group leaders: Else Marit Inderberg and Sebastien Wälchli's group), received NOK 83 million to pursue their development on TCR-redirected NK cells !

We are very happy that an innovation developped five years ago by the early team (G. Gaudernack, G. Kvalheim, EM Inderberg and S. Wälchli) is now being developed as a therapeutic product. We thank our co-workers for their hard work, Inven2 for their support in the commercial development, and NFR, Helse Sør-Øst and Kreftforeningen  for their financial support and guidance.  

The team in Boston concluded that lobster is better than business:

The concept (with the old name):

Design: P. Dillard

Find more about this here !

New review on TCR therapy against melanoma

Process of T cell therapy production for patient use

We published a new review in Scandinavian Journal of Immunology on how to adapt TCR redirected T-cells therapy to fight melanoma!

Make sure to have a look here!

New review!

We published a review on putative targets in ovarian cancer for CAR therapy in Scandinavian Journal of Immunology! Make sure to have a look here!


Hakan Köksal, Ph.D.

Hakan Köksal successfully defended his Ph.D. entitled “Novel designs and approaches in CAR T cells” Thursday 28th May.

All of his colleagues are proud of his work and his achievements!

PhD defense: Hakan Köksal

M.Sc Hakan Köksal at Institute of Clinical Medicine will be defending the thesis “Novel designs and approaches in CAR T cells” for the degree of PhD (Philosophiae Doctor).

Due to the current pandemic situation, the University of Oslo is closed and the public defence will be held as a video conference over Zoom here.

The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.

New case report!

Else Marit Inderberg and Nadia Mensali took part in a paper showing the treatment of posttransplantation lymphoproliferative disease by using retransplantation, make sure to check it here!

New papers

Baoyan Bai, June Helen Myklebust and Sébastien Wälchli just published a protocol on how to edit B cell lymphoma using CRISPR/Cas9 technology, make sure to have a look here!

Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology



Sébastien Wälchli and Mouldy Sioud published also a protocol on CRISPR/Cas9 as a tool for adoptive cell therapy. More information here!

Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?


Finally, Nicholas Casey published recently a paper on the use of RNAi with TCR transfer to enhance safety and efficiency. Follow the guide!


New review !

A new review from Else Marit Inderberg and Sebastien Wälchli was published in Cancer Immunology, Immunotherapy. The review described how we can isolate and identify therapeutic TCRs from long-term surviving patients.

Make sure to have a look here!

New publication !

Nadia Mensali and Marit R. Myhre published a new study entitled: "Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy". A copy of the study published in Cancer Immunology, Immunotherapy can be found here.

Two news, one stone !

We were at the last PIVAC (Progress in Vaccination Against Cancer) 2019 !

Else Marit and Hedvig presented our most recent developments !

Make sure to check their abstracts !

Yesterday Lizet Baken successfully defended her Bachelor Thesis at the Avans University of Applied Sciences.

Part of this thesis was performed in our lab where she has been working on an anti-Ig-lambda CAR.

Congratulations Lizet, we are all very proud of you!

We will be at CIMT 2019



Else Marit Inderberg, Sebastien Wälchli, Nadia Mensali and Elizabeth Baken will attend CIMT 2019 meeting in Mainz (21 to 23 May).

Make sure to look at their abstracts.

CIMT website

CIMT program

First norwegian CAR publication!

We published pre-clinical results of the first 100% Norwegian CAR: CD37CAR, an alternative to CD19CAR.

Make sure to have a look here and here !

Hakan Köksal And Pierre Dillard are first authors of this publication.


We will be at AACR 2019


Gunnar Kvalheim, Hakan Köksal and Pierre Dillard will be at the next AACR meeting (29th of March to 3rd of April, Atalanta) to talk about new developments in CAR.

Hakan will present a novel combination method for IGKCAR that prevents B-cell aplasia.

Pierre will present the pre-clinical validation of CD37CAR, an alternative to CD19CAR.

Make sure to have a look!

A new Postdoc joined us !

Emmanuelle Benard who did her PhD in Biophysics and Immunology in Marseille, just joined us ! 

She will be in charge of the development of new CAR T-cells.

First JOVE shooting

We had our first JOVE shooting on a new metod to generate spheroid for CAR T-cells screening.

Make sure to give it a look (once it is out) !


PIVAC 2018 was held in Oslo

PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy. 

We will be at CIMT 2018!



Gunnar Kvalheim, Else Marit Inderberg, Sebastien Wälchli and Nadia Mensali will attend CIMT 2018 meeting in Mainz (15 to 17 May).

Make sure to look at their abstracts.

CIMT website

CIMT program

We will be at AACR 2018



Pierre Dillard will attend the 2018 meeting of the American Association for Cncer Research (AACR). He will present our recent work on universal killer, make sure to have a look !

New publication from our group in Cancer Immunology

Human c-SRC kinase (CSK) overexpression makes T cells dummy

Patient safety upon immunotherapy treatment is a challenge that still need to be adressed.

In this publication we report how by affecting c-SRC kinase we can make T-cells "dummy": effector cells are still able to recognize and bind to the target but unable to carry on with their activation. This mechanism could potentially open the way for a safe-lock system permitting to reduce off-target toxicity.

Image from: Ellen Tenstad/Science Shaped

We will be at SITC 2017 !


Nadia Mensali and Pierre Dillard will attend the 2017 meeting of the Society for ImmunoTherapy of Cancer (SITC). They will present our recent work on universal killer and CD4 Adoptive cell therapy, make sure to have a look !

We will be at PIVAC 2017 at the end of September

 Marit Renee Myhre has been selected to give a talk at  the 17th International Conference on Progress in  Vaccination Against Cancer (PIVAC 2017) in Loutraki,  Corinth, Greece

 She will present our latest work on our new CD4-based therapy, make sure to have a look at the abstract if you want  to learn more !


New publication: therapeutic T-cell receptors in healthy donor blood, is safety predictable?

Our team has published a new paper in Translational Cancer Research:

New publication in our team: therapeutic T-cell receptors in healthy donor blood, is safety predictable? by Hakan Köksal and Sébastien Wälchli.
They are commenting a paper published in 2017 in Blood by Jahn et al. that presents a novel TCR-based therapy trageting intracellular transcription factor. Make sure to have a look at both papers!